Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Engineering bone from fat: a review of the in vivo mechanisms of adipose derived stem cell-mediated bone regeneration.

Horenberg AL., Rindone AN., Grayson WL.

Narrative Review on Immune Modulation, published in Prog Biomed Eng (Bristol) (2021) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Prog Biomed Eng (Bristol) (2021)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41367042
DOI
10.1088/2516-1091/ac1522
Citations
1

Abstract (original English)

Adipose-derived stromal/stem cells (ASCs) have considerable potential to promote bone regeneration due to their ease of isolation, abundance, and osteogenic capacity. However, despite two decades of research, studies of the precise mechanisms underlying their in vivo osteo-regenerative capacity remain contradictory. Specifically, there are multiple reports that suggest either a direct mechanism (i.e. ASCs directly differentiate into osteoblasts and lay done new bone matrix) or an indirect mechanism (i.e. ASCs stimulate endogenous cells via their secretory profiles) of bone regeneration. To address this discrepancy we critically reviewed studies utilizing ASCs for in vivo bone regeneration and employed methods to track cell fate. We evaluated the rigor of individual studies by examining the specific defect and animal models employed, cell sorting or pretreatment methods, and quantitative assessments of cell dosing and cell survival/distribution data to determine the strength of their claims. There is robust evidence to support both a direct differentiation of ASCs and indirect signaling based on secreted factors: osteogenic/angiogenic, immunomodulatory, or extracellular matrix factors, suggesting that a combination of factors underlie the pro-regenerative capacity of ASCs. However, there remains significant knowledge gaps regarding the precise efficiency of ASC engraftment follo

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research